Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

trml

Cash and Short Term Investments

Last Annual Value

258.30M

3-Year CAGR

2%

5-Year CAGR

46%

10-Year CAGR

21%

Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Competitors Analysis of Cash and Short Term Investments

TRML · NASDAQ
CompanyCash and Short Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
258.30M
8.4%1.1%N/A 
316.98M
-5.1%27.0%N/A
404.30M
32.5%18.0%56.7%
462.62M
22.3%33.3%N/A
281.49M
10.6%3.5%N/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
97.86M
15.9%-2.1%-8.5%
554.52M
-9.6%-10.4%N/A
394.07M
-12.0%-2.5%14.1%
1.02B
57.0%43.8%N/A
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

Intrinsic Value
Current Price: $47.98